On August 3, 2026, Switzerland's Federal Office of Public Health (BAG) published new Grundlagenbeurteilungen for the Spezialitaetenliste (SL), the definitive register of medicines reimbursed by the compulsory health insurance (OKP). The batch sets fresh limitation conditions for Boehringer Ingelheim's Ofev (nintedanib) in two interstitial lung disease indications from August 1, 2026, and rewrites the reimbursement perimeter for AstraZeneca's Lynparza (olaparib) across four oncology indications while admitting a fifth, plus admits Roche's Polivy (polatuzumab vedotin) for lymphoma, all time-limited, from July 1, 2026.
For Swiss market-access, HEOR and medical teams at the three originators, and for Krankenversicherer processing Kostengutsprache (prior cost approval) requests, the published assessment bases are now the operative text: OKP reimbursement tracks the SL limitation wording verbatim, and the time-limited (befristet) admissions carry a reassessment sunset the companies must prepare for. The decisions are published on the BAG's SL publications page pursuant to Article 71 paragraph 1 letter b of the Health Insurance Ordinance (KVV, SR 832.102).
What changed for Ofev's interstitial lung disease indications?
Ofev's SL entries for systemic sclerosis-associated interstitial lung disease (SSc-ILD) and progressive fibrosing interstitial lung disease (PF-ILD) each received a new Limitierungsaenderung effective August 1, 2026. The BAG published the SSc-ILD assessment and the PF-ILD assessment as separate PDFs, each restating the effectiveness, appropriateness and economicity (WZW) grounds and the precise patient population the OKP will cover.
A limitation change does not delist the product; it redefines the reimbursed population. Boehringer's Swiss affiliate must align prescribing and reimbursement-request documentation with the new wording immediately, because insurers apply the SL limitation text as the binding test for Kostengutsprache approval from the effective date.
How do the Lynparza changes reshape ovarian, breast and prostate cancer reimbursement?
Lynparza received the heaviest revision in the batch: four Limitierungsaenderungen and one Neuaufnahme, all marked befristet (time-limited) and effective July 1, 2026. The limitation changes cover early high-risk breast cancer, ovarian cancer after first-line chemotherapy as monotherapy, ovarian cancer after first-line chemotherapy in combination with bevacizumab, and prostate cancer. A separate Neuaufnahme admits Lynparza for ovarian cancer with platinum-sensitive relapse, also time-limited.
The befristet flag is the operative constraint: BAG grants SL reimbursement for a fixed period, after which the originator must submit a fresh dossier or lose OKP coverage for that indication. AstraZeneca's market-access team should diary the reassessment window now and confirm whether real-world utilisation data will be expected at renewal. Because four indications had their limitation text rewritten simultaneously, medical affairs should verify that field materials and Kostengutsprache templates still match the new population descriptors.
What does Polivy's time-limited admission mean for lymphoma treatment?
The BAG admitted Roche's Polivy to the SL effective July 1, 2026, on a befristet basis, with the assessment basis setting out the WZW justification and the reimbursed indication scope. A time-limited new admission means Polivy is now reimbursable in the OKP, but the listing is not permanent: Roche must prepare for a reassessment within the period BAG fixes, and prescribers should expect a defined treatment-line or patient-population restriction in the limitation text.
| Product (indication) | Decision type | Effective | Befristet flag |
|---|---|---|---|
| Ofev (SSc-ILD) | Limitation change | August 1, 2026 | Not flagged |
| Ofev (PF-ILD) | Limitation change | August 1, 2026 | Not flagged |
| Lynparza (4 indications) | Limitation change | July 1, 2026 | Yes |
| Lynparza (platinum-sensitive relapse ovarian) | New admission | July 1, 2026 | Yes |
| Polivy | New admission | July 1, 2026 | Yes |
Take advantage of this real-time watch
For originators running launches across Switzerland, the practical point is that continuous, per-jurisdiction real-time monitoring surfaces SL limitation changes the moment BAG publishes them, before prescribers and insurers hit the mismatch.
Next steps: pull the four Lynparza and two Ofev PDFs plus the Polivy assessment from the BAG page and diff the new limitation text against your current Kostengutsprache templates; confirm the befristet reassessment deadlines with regulatory affairs; brief medical and field teams on the effective dates (July 1 for Lynparza and Polivy, August 1 for Ofev); and verify that insurer-facing reimbursement messaging no longer relies on the prior limitation wording.
